Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.

Papillary thyroid cancer prognosis: an evolving field / Ulisse, S.; Baldini, E.; Lauro, A.; Pironi, D.; Tripodi, D.; Lori, E.; Ferent, I. C.; Amabile, M. I.; Catania, A.; Di Matteo, F. M.; Forte, F.; Santoro, A.; Palumbo, P.; D'Andrea, V.; Sorrenti, S.. - In: CANCERS. - ISSN 2072-6694. - 13:21(2021). [10.3390/cancers13215567]

Papillary thyroid cancer prognosis: an evolving field

Ulisse S.
;
Baldini E.;Lauro A.;Pironi D.;Tripodi D.;Lori E.;Ferent I. C.;Amabile M. I.;Catania A.;Di Matteo F. M.;Forte F.;Santoro A.;Palumbo P.;D'andrea V.;Sorrenti S.
2021

Abstract

Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.
2021
BRAF; estrogen receptor; MiRNA; molecular pathogenesis; plasminogen activating system; prognosis; TERT promoter; therapy; thyroid cancers; TNM; tumor molecular profiling
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Papillary thyroid cancer prognosis: an evolving field / Ulisse, S.; Baldini, E.; Lauro, A.; Pironi, D.; Tripodi, D.; Lori, E.; Ferent, I. C.; Amabile, M. I.; Catania, A.; Di Matteo, F. M.; Forte, F.; Santoro, A.; Palumbo, P.; D'Andrea, V.; Sorrenti, S.. - In: CANCERS. - ISSN 2072-6694. - 13:21(2021). [10.3390/cancers13215567]
File allegati a questo prodotto
File Dimensione Formato  
Ulisse_Papillary-thyroid-cancer_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 865.51 kB
Formato Adobe PDF
865.51 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1585394
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 52
social impact